Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK and Safety Study of Migalastat in Fabry Disease With Severe Renal Impairment or Hemodialysis
jRCT2051220125Active, not recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Jan 2023
- Modality
- Classical Binding Small Molecules → Small Molecules
01
Overview
Open-label trial of migalastat in Fabry disease (FD) (2 cohorts), sponsored by Amicus Therapeutics. Primary endpoints: Maximum observed concentration (Cmax), Time to maximum concentration (tmax) and 20 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on jRCT2051220125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220125.